CAR-T Companies Hang Onto Novartis' Coat-Tails After Historic FDA Panel Vote

13 Jul 2017

The FDA panel landmark recommendation for Novartis' CTL019 should provide a fillip for the other players in the CAR-T field but the response from the investment community has been lukewarm compared with researchers and patients.

Human tower — Standing strong: FDA panel nod may boost other CAR-T players • Source: Shutterstock

The momentous news that the FDA's Oncologic Drugs Advisory Committee has recommended approval of Novartis AG’s CTL019 has provided a boost not only for the Swiss major but for the rest of the players in the chimeric antigen receptor T cell (CAR-T) market.

The ODAC voted 10-0 in favor of CTL019 (tisagenlecleucel) for pediatric leukemia, a decision that as good as guarantees that the therapy, developed by extracting cells, reengineering them to target CD19 to fight cancer and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

05 May 2025

• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label

28 Apr 2025

• By Joseph Haas

With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

28 Apr 2025

• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

25 Apr 2025

• By Alaric DeArment

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.